NCT02829372View on ClinicalTrials.gov

Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

PHASE1TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
HER2 Expressing Solid Tumours
Interventions
DRUG

CD3/HER2 bispecific monoclonal antibody

Increasing doses, IV on day 1 and 15 of each 28 day cycle

Trial Locations (8)

10117

Glenmark Investigational Site 103, Berlin

48201

Glenmark Investigational Site 209, Detroit

50670

Glenmark Investigational Site 102, Cologne

55131

Glenmark Investigational Site 104, Mainz

66205

Glenmark Investigational Site 204, Fairway

75230

Glenmark Investigational Site 201, Dallas

84112

Glenmark Investigational Site 203, Salt Lake City

01307

Glenmark Investigational Site 101, Dresden

Sponsors

Lead Sponsor

Ichnos Sciences SA
All Listed Sponsors
collaborator

Glenmark Pharmaceuticals S.A.

INDUSTRY

lead

Ichnos Sciences SA

INDUSTRY

NCT02829372 - Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers | Biotech Hunter | Biotech Hunter